Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788470 | 0.87 | CSF1R (0.51) | NPC1RAB9ATP53THRBMAPK1 | |
| SCHEMBL1844413 | 0.84 | MAPK1 (0.50) | NPC1RAB9ATP53THRBMAPK1 | |
| SCHEMBL1544213 | 0.84 | MAPK1 (0.50) | NPC1RAB9ATP53THRBMAPK1 | |
| SCHEMBL16504181 | 0.84 | MAPK1 (0.50) | NPC1RAB9ATP53THRBMAPK1 | |
| SCHEMBL19311899 | 0.84 | NPC1 (0.49) | NPC1RAB9ATHRBSMN1; SMN2NOTUM | |
| SCHEMBL16044670 | 0.84 | NPC1 (0.49) | NPC1RAB9ATHRBSMN1; SMN2NOTUM | |
| SCHEMBL16088990 | 0.83 | RAB9A (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2NOTUM | |
| SCHEMBL11804742 | 0.83 | RAB9A (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2NOTUM | |
| SCHEMBL13871020 | 0.82 | MAPK1 (0.48) | NPC1RAB9ATP53THRBMAPK1 | |
| SCHEMBL2896497 | 0.82 | MAPK1 (0.48) | NPC1RAB9ATP53THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | NPC1 934/4885RAB9A 854/4885TP53 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.